Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Tondini, Carlo"'
Autor:
Dettorre GM; Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK., Dolly S; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK., Loizidou A; Department of Infectious Diseases, Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Chester J; Medical Oncology, School of Medicine, Cardiff University, Cardiff, UK.; Medical Oncology, Velindre Cancer Centre, Cardiff, UK., Jackson A; Clinical Trials, Velindre Cancer Centre, Cardiff, UK., Mukherjee U; Medical Oncology, Barts Health NHS Trust, London, UK., Zambelli A; Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy., Aguilar-Company J; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.; Infectious Diseases, Vall d'Hebron University Hospital, Barcelona, Spain., Bower M; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK., Sng CCT; Cancer Division, University College London Hospitals, London, UK., Salazar R; Department of Medical Oncology, ICO L'Hospitalet, Oncobell Program (IDIBELL), CIBERONC, Hospitalet de Llobregat, Spain., Bertuzzi A; Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy., Brunet J; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain., Mesia R; Department of Medical Oncology, Catalan Institute of Oncology, Badalona, Spain., Sita-Lumsden A; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK., Seguí E; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain., Biello F; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale and Maggiore della Carità Hospital, Novara, Italy., Generali D; Multidisciplinary Breast Pathology and Translational Research Unit, ASST Cremona, Cremona, Italy.; Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy., Grisanti S; Medical Oncology Unit, Spedali Civili, Brescia, Italy., Seeva P; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK., Rizzo G; Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Libertini M; Medical Oncology Unit, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy., Maconi A; Infrastruttura Ricerca Formazione Innovazione, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy., Moss C; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK., Russell B; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK., Harbeck N; Department of Gynecology and Obstetrics, Breast Center and Gynecological Cancer Center and CCC Munich, University Hospital Munich, Munich, Germany., Vincenzi B; Medical Oncology, Policlinico Universitario Campus Bio-Medico, Rome, Italy., Bertulli R; Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Ottaviani D; Cancer Division, University College London Hospitals, London, UK., Liñan R; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain., Marrari A; Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy., Carmona-García MC; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain., Chopra N; Cancer Division, University College London Hospitals, London, UK., Tondini CA; Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy., Mirallas O; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain., Tovazzi V; Medical Oncology Unit, Spedali Civili, Brescia, Italy., Fotia V; Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy., Cruz CA; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain., Saoudi-Gonzalez N; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain., Felip E; Department of Medical Oncology, Catalan Institute of Oncology, Badalona, Spain., Roqué A; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain., Lee AJX; Cancer Division, University College London Hospitals, London, UK., Newsom-Davis T; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK., García-Illescas D; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain., Reyes R; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain., Wong YNS; Cancer Division, University College London Hospitals, London, UK., Ferrante D; Department of Translational Medicine, Unit of Cancer Epidemiology, CPO-Piemonte, University of Eastern Piedmont, Novara, Italy., Scotti L; Department of Translational Medicine, Unit of Cancer Epidemiology, CPO-Piemonte, University of Eastern Piedmont, Novara, Italy., Marco-Hernández J; Department of Internal Medicine, Hospital Clinic, Barcelona, Spain., Ruiz-Camps I; Infectious Diseases, Vall d'Hebron University Hospital, Barcelona, Spain., Patriarca A; Division of Haematology, Department of Translational Medicine, University of Piemonte Orientale and Maggiore della Carità Hospital, Novara, Italy., Rimassa L; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 20090 Pieve Emanuele, Milan, Italy., Chiudinelli L; Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy., Franchi M; Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy., Santoro A; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 20090 Pieve Emanuele, Milan, Italy., Prat A; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain., Gennari A; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale and Maggiore della Carità Hospital, Novara, Italy., Van Hemelrijck M; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK.; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK., Tabernero J; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain., Diamantis N; Medical Oncology, Barts Health NHS Trust, London, UK., Pinato DJ; Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK david.pinato@imperial.ac.uk.; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale and Maggiore della Carità Hospital, Novara, Italy.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Mar; Vol. 9 (3).
Autor:
Mandala M; Unit of Medical Oncology, University of Perugia, Perugia, Italy mario.mandala@unipg.it., Lorigan P; Medical Oncology-Melanoma, The Christie Hospital NHS Trust, Manchester, UK.; Division of cancer sciences, The University of Manchester, Manchester, UK., De Luca M; Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Lombardia, Italy., Bianchetti A; Oncology, Fondazione per la Ricerca Ospedale Maggiore, Bergamo, Italy., Merelli B; Unit of Medical Oncology, Department of Oncology and Hematology, ASST Papa Giovanni XXIII, Bergamo, Lombardia, Italy., Bettini AC; Oncology, Department of Oncology and Hematology, ASST Papa Giovanni XXIII, Bergamo, Lombardia, Italy., Bonomi L; Oncology, Department of Oncology and Hematology, ASST Papa Giovanni XXIII, Bergamo, Lombardia, Italy., Nahm S; Medical Oncology-Melanoma, The Christie Hospital NHS Trust, Manchester, UK., Vitale MG; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy., Negrini G; Oncology, Department of Oncology and Hematology, ASST Papa Giovanni XXIII, Bergamo, Lombardia, Italy., Di Croce A; Unit of Medical Oncology, Department of Oncology and Hematology, ASST Papa Giovanni XXIII, Bergamo, Lombardia, Italy., Ascierto PA; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy., Rulli E; Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Lombardia, Italy., Tondini CA; Unit of Medical Oncology, Department of Oncology and Hematology, ASST Papa Giovanni XXIII, Bergamo, Lombardia, Italy.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Feb; Vol. 9 (2).
Autor:
Rogiers A; Melanoma Institute Australia and University of Sydney, Sydney, New South Wales, Australia., Pires da Silva I; Melanoma Institute Australia and University of Sydney, Sydney, New South Wales, Australia.; Westmead and Blacktown Hospitals, Sydney, New South Wales, Australia., Tentori C; FROM Fondazione per la Ricerca Ospedale Maggiore, Bergamo, Italy., Tondini CA; Papa Giovanni XXIII Hospital, Bergamo, Italy., Grimes JM; Columbia University Irving Medical Center, New York City, New York, USA., Trager MH; Columbia University Irving Medical Center, New York City, New York, USA., Nahm S; The Christie NHS Foundation Trust, Manchester, UK., Zubiri L; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Manos M; Dana Farber Cancer Institute, Boston, Massachusetts, USA., Bowling P; Dana Farber Cancer Institute, Boston, Massachusetts, USA., Elkrief A; Segal Cancer Centre Jewish General Hospital, McGill University, Montreal, Québec, Canada., Papneja N; Segal Cancer Centre Jewish General Hospital, McGill University, Montreal, Québec, Canada., Vitale MG; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy., Rose AAN; Princess Margaret Cancer Centre - University Health Network, Toronto, Ontario, Canada., Borgers JSW; Netherlands Cancer Institute, Amsterdam, The Netherlands., Roy S; Gustave Roussy and Paris-Saclay University, Villejuif, France., Mangana J; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland., Pimentel Muniz T; Princess Margaret Cancer Centre - University Health Network, Toronto, Ontario, Canada., Cooksley T; The Christie NHS Foundation Trust, Manchester, UK., Lupu J; Gustave Roussy and Paris-Saclay University, Villejuif, France., Vaisman A; Princess Margaret Cancer Centre - University Health Network, Toronto, Ontario, Canada., Saibil SD; Princess Margaret Cancer Centre - University Health Network, Toronto, Ontario, Canada., Butler MO; Princess Margaret Cancer Centre - University Health Network, Toronto, Ontario, Canada., Menzies AM; Melanoma Institute Australia and University of Sydney, Sydney, New South Wales, Australia.; Royal North Shore Hospital and Mater Hospital, Sydney, New South Wales, Australia., Carlino MS; Melanoma Institute Australia and University of Sydney, Sydney, New South Wales, Australia.; Westmead and Blacktown Hospitals, Sydney, New South Wales, Australia., Erdmann M; Comprehensive Cancer Center Erlangen - EMN, University Medical Center Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany., Berking C; Comprehensive Cancer Center Erlangen - EMN, University Medical Center Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany., Zimmer L; University Hospital Essen & German Cancer Consortium, Partner Site, Essen, Germany., Schadendorf D; University Hospital Essen & German Cancer Consortium, Partner Site, Essen, Germany., Pala L; European Institute of Oncology, Milan, Italy., Queirolo P; Division of Melanoma, Sarcomas and Rare Tumors, IEO, European Institute of Oncology, IRCCS, Milan, Italy., Posch C; Technical University of Munich, German Cancer Consortium (DKTK), Munich, Germany., Hauschild A; University Hospital Schleswig-Holstein, Kiel, Germany., Dummer R; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland., Haanen J; Netherlands Cancer Institute, Amsterdam, The Netherlands., Blank CU; Netherlands Cancer Institute, Amsterdam, The Netherlands., Robert C; Gustave Roussy and Paris-Saclay University, Villejuif, France., Sullivan RJ; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy., Miller WH Jr; Segal Cancer Centre Jewish General Hospital, McGill University, Montreal, Québec, Canada., Stephen Hodi F; Dana Farber Cancer Institute, Boston, Massachusetts, USA., Suijkerbuijk KPM; University Medical Center Utrecht, Utrecht, The Netherlands., Reynolds KL; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Rahma OE; Dana Farber Cancer Institute, Boston, Massachusetts, USA., Lorigan PC; The Christie NHS Foundation Trust, Manchester, UK.; University of Manchester, Manchester, UK., Carvajal RD; Columbia University Irving Medical Center, New York City, New York, USA., Lo S; Melanoma Institute Australia and University of Sydney, Sydney, New South Wales, Australia., Mandala M; Unit of Medical Oncology, University of Perugia, Perugia, Italy., Long GV; Melanoma Institute Australia and University of Sydney, Sydney, New South Wales, Australia georgina.long@sydney.edu.au.; Royal North Shore Hospital and Mater Hospital, Sydney, New South Wales, Australia.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Jan; Vol. 9 (1).
Autor:
Rutkowski P; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Warszawa, Poland., Indini A; Oncology and Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy., De Luca M; Istituto di Ricerche Farmacologiche Mario Negri Sede di Milano, Milano, Lombardia, Italy., Merelli B; Oncology and Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy., Mariuk-Jarema A; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Warszawa, Poland., Teterycz P; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Warszawa, Poland., Rogala P; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Warszawa, Poland., Lugowska I; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Warszawa, Poland., Cybulska-Stopa B; Maria Sklodowska-Curie Institute of Oncology Krakow, Krakow, Poland., Labianca A; Oncology and Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy., Di Guardo L; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy., Del Vecchio M; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy., Pigozzo J; Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico, Padova, Veneto, Italy., Randon G; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy., Corti F; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy., Tondini CA; Oncology and Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy., Rulli E; Istituto di Ricerche Farmacologiche Mario Negri Sede di Milano, Milano, Lombardia, Italy., Mandala M; Oncology and Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy mmandala@asst-pg23.it.; University of Perugia, Perugia, Italy.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Nov; Vol. 8 (2).
Autor:
Passardi A; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Rizzo M; Department of Medical Oncology, Azienda Provinciale per i Servizi Sanitari, Trento, Italy., Maines F; Department of Medical Oncology, Azienda Provinciale per i Servizi Sanitari, Trento, Italy., Tondini C; Department of Medical Oncology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy., Zambelli A; Department of Medical Oncology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy., Vespignani R; IT Service, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Andreis D; Biostatistics and Clinical Trials Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Massa I; Biostatistics and Clinical Trials Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Dianti M; Center for Information and Communication Technology, eHealth Unit, Fondazione Bruno Kessler, Trento, Italy., Forti S; Center for Information and Communication Technology, eHealth Unit, Fondazione Bruno Kessler, Trento, Italy., Piras EM; Center for Information and Communication Technology, eHealth Unit, Fondazione Bruno Kessler, Trento, Italy., Eccher C; Center for Information and Communication Technology, eHealth Unit, Fondazione Bruno Kessler, Trento, Italy.
Publikováno v:
BMJ open [BMJ Open] 2017 May 29; Vol. 7 (5), pp. e014617. Date of Electronic Publication: 2017 May 29.